UBS Group’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-359,939
| Closed | -$14.3M | – | 10508 |
|
|
2026
Q1 | $14.3M | Sell |
359,939
-177,579
| -33% | -$4.54M | ﹤0.01% | 2953 |
|
|
2025
Q4 | $13.4M | Buy |
537,518
+452,340
| +531% | +$11.5M | ﹤0.01% | 2983 |
|
|
2025
Q3 | $2.07M | Sell |
85,178
-124,572
| -59% | -$2.21M | ﹤0.01% | 4917 |
|
|
2025
Q2 | $2.76M | Buy |
209,750
+136,267
| +185% | +$1.73M | ﹤0.01% | 4483 |
|
|
2025
Q1 | $1.06M | Sell |
73,483
-996,726
| -93% | -$16.3M | ﹤0.01% | 5249 |
|
|
2024
Q4 | $17.9M | Buy |
1,070,209
+1,065,202
| +21,274% | +$17.6M | ﹤0.01% | 2445 |
|
|
2024
Q3 | $80.1K | Buy |
5,007
+2,198
| +78% | +$26.9K | ﹤0.01% | 6507 |
|
|
2024
Q2 | $25.4K | Buy |
2,809
+931
| +50% | +$8.83K | ﹤0.01% | 7149 |
|
|
2024
Q1 | $21.2K | Buy |
1,878
+295
| +19% | +$2.79K | ﹤0.01% | 6906 |
|
|
2023
Q4 | $12.6K | Sell |
1,583
-1,053
| -40% | -$7.06K | ﹤0.01% | 7341 |
|
|
2023
Q3 | $17.1K | Buy |
2,636
+518
| +24% | +$3.54K | ﹤0.01% | 6887 |
|
|
2023
Q2 | $13.1K | Sell |
2,118
-3,045
| -59% | -$14.4K | ﹤0.01% | 7048 |
|
|
2023
Q1 | $19.9K | Buy |
5,163
+2,577
| +100% | +$9.43K | ﹤0.01% | 7086 |
|
|
2022
Q4 | $8.02K | Buy |
2,586
+1,028
| +66% | +$3.81K | ﹤0.01% | 8829 |
|
|
2022
Q3 | $6K | Buy |
+1,558
| New | +$7.13K | ﹤0.01% | 9011 |
|
|
2022
Q1 | – | Sell |
-496
| Closed | -$6K | – | 10324 |
|
|
2021
Q4 | $6K | Buy |
496
+275
| +124% | +$3.7K | ﹤0.01% | 9257 |
|
|
2021
Q3 | $4K | Sell |
221
-457
| -67% | -$9.46K | ﹤0.01% | 8629 |
|
|
2021
Q2 | $15K | Buy |
+678
| New | +$15.9K | ﹤0.01% | 7638 |
|
UBS Group's CNTA Position: Q2 2026 in Review
UBS Group sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 359,939 shares — an estimated $14.3M sold.
UBS Group first reported a position in CNTA in Q2 2021 and held it in 18 quarters. The position peaked at $17.9M in Q4 2024. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- UBS Group reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 359,939 Centessa Pharmaceuticals shares in Q2 2026, an estimated $14.3M.
- UBS Group first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 18 quarters.
- UBS Group's Centessa Pharmaceuticals position peaked at $17.9M in Q4 2024.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.